Asciminib RMP Study
About the study
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion criteria
- Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive Scemblix® treatment according to locally approval label
- Patients who are willing to provide written informed consent prior to study enrollment
EXCLUSION CRITERIA
Exclusion criteria
- Patients with contraindication according to locally approved label of Scemblix®
- Patients who receive or are going to receive any investigational medicine during the observation period
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Chronic Myeloid Leukemia
Age
18 - 100
Participants Needed
100
Est. Completion Date
Jul 31, 2025
Treatment Type
OBSERVATIONAL
Sponsor
Novartis
ClinicalTrials.gov NCT Identifier
NCT05943522
Study Number
CABL001A2006
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?